Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Windtree TherapeuticsWINT +100.00% EV-to-EBITDA is -0.30 as of Jul. 31, 2026. The stock has 2 warning signs investors should review. Among 411 Biotechnology companies, Windtree Therapeutics ranks worse than 243308.76% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Windtree Therapeutics's enterprise value is $12.74 Mil.
Windtree Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 was $-42.60 Mil. Therefore, Windtree Therapeutics's EV-to-EBITDA for today is -0.30.
The historical rank and industry rank for Windtree Therapeutics's EV-to-EBITDA or its related term are showing as below:
WINT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.3 Med: 0 Max: 0
Current: -0.3
WINT's EV-to-EBITDA is ranked worse than 100% of 411
companies
in the Biotechnology industry
Industry Median: 12.05
vs WINT: -0.30
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Windtree Therapeutics's PE Ratio (TTM) for today is calculated as:
Windtree Therapeutics's share price for today is $0.0004.
Windtree Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.505.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Windtree Therapeutics EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Windtree Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Windtree Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windtree Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Windtree Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Windtree Therapeutics's EV-to-EBITDA falls into.
Windtree Therapeutics's current Enterprise Value is $12.74 Mil.
Windtree Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-42.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Windtree Therapeutics (WINT) has a EV-to-EBITDA of -0.30 as of Jul. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Windtree Therapeutics. According to the industry distribution chart, Windtree Therapeutics ranks #999999 out of 411 companies in the Biotechnology industry.
Is Windtree Therapeutics' EV-to-EBITDA too high?
Windtree Therapeutics' current EV-to-EBITDA is -0.30. Based on the distribution chart, Windtree Therapeutics ranks #999999 out of 411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Windtree Therapeutics' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Windtree Therapeutics ranks #999999 out of 411 companies for EV-to-EBITDA. This places Windtree Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 12.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.05, based on 411 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Windtree Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 12.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windtree Therapeutics's current EV-to-EBITDA is -0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windtree Therapeutics stock overvalued right now?
Windtree Therapeutics (WINT) has a current EV-to-EBITDA of -0.30. The current EV-to-EBITDA is -0.30. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Windtree Therapeutics (WINT), the current EV-to-EBITDA is -0.30 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WINT has been successfully added to your 
